Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease

Maciej Bochenek · Jarosław Zalewski · Jerzy Sadowski · Anetta Undas

Published online: 20 October 2012
© The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract Altered fibrin clot structure has been reported both in patients with coronary artery disease (CAD) and those with type 2 diabetes mellitus (DM2). The aim of the present study was to evaluate plasma fibrin clot permeability and susceptibility to lysis in patients with DM2 and CAD. We studied 132 consecutive CAD patients, including 67 subjects with DM2, scheduled for elective coronary artery bypass grafting surgery. Ex vivo plasma fibrin clot permeability (Ks) and lysis time (t50%) induced by 1 μg/mL recombinant tissue plasminogen activator (tPA), along with plasma levels of plasminogen activator inhibitor-1 (PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI), tPA, von Willebrand factor (vWF), P-selectin, soluble CD40 ligand (sCD40L), were measured. Diabetic and non-diabetic patients did not differ in regard to demographics and remaining cardiovascular risk factors. Concomitant DM2 was associated with higher glucose (+24.3%, p < 0.001), fibrinogen (+9.0%, p = 0.037), PAI-1 (+58.7%, p < 0.001), tPA (+24.0%, p < 0.001) and P-selectin (+12.2%, p < 0.001). Compared with the non-diabetic group, the CAD patients with DM2 had lower Ks (-6.1%, p = 0.02) and prolonged t50% (+5.1%, p = 0.04). Multiple regression analysis of the whole study group showed that vWF, PAI-1, fibrinogen and DM2 were the independent predictors of t50% (R² = 0.58, p < 0.001), while only vWF was an independent predictor of Ks (R² = 0.22, p < 0.001). This study indicates that DM2 is potent enough to unfavorably affect plasma fibrin clot characteristics despite abnormal clot phenotype typically observed in CAD. Of note, platelet and endothelial markers appear to contribute to fibrin clot properties in CAD concomitant with DM2.

Keywords Coronary artery disease · Diabetes mellitus · Fibrin clot · Fibrinolysis · Platelet activation

Introduction

Type 2 diabetes mellitus (DM2) is an independent risk factor of coronary artery disease (CAD) and increases the risk of CAD two to three times [1]. Up to 21.4% of patients with CAD has DM2 [2]. Moreover, the coexistence of DM2 and CAD impairs cardiovascular prognosis and increases the risk of ischemic events [3, 4]. This observation can be explained by several mechanisms, including concomitant risk factors such as arterial hypertension, obesity, and metabolic abnormalities such as hyperglycemia, hyperinsulinemia, insulin resistance and dyslipidemia, which are responsible for endothelial dysfunction [5]. It has been demonstrated that atherosclerotic plaques in DM2 patients are more prone to rupture [6].

Both DM2 as well as CAD have been reported to unfavorably affect structural and functional characteristics of a fibrin clot relatively resistant to mechanical and enzymatic degradation [7–9]. Fibrin clot structure and functions depend on several genetic and environmental factors present in both clinical entities, including enhanced inflammatory status and oxidative stress [10]. Altered fibrin clot architecture and function both in CAD and DM2 are characterized by lower fibrin clot permeability resulting from a smaller pore size in the fiber network, along with
impaired susceptibility to lysis [7–12]. Specifically, the altered fibrin structure in DM2 is largely attributed to glycation of fibrinogen and fibrin [9], which may interfere with fibrin polymerization, cross-linking by FXIII, tissue plasminogen activator (tPA) and plasminogen binding and plasminogen to plasmin conversion [8]. However, the data on this association are not consistent [13]. Moreover, fibrinogen is the main determinant of fibrin clot characteristics and increased fibrinogen levels are commonly observed in DM2. This abnormality results in formation of more compact fibrin clots [13]. Hyperfibrinogenemia has also been reported in several cohorts of CAD patients free of DM2 and implicated in a higher risk of myocardial infarction (MI) [14–16]. Importantly, there is evidence that fibrin is a consistent component of atherosclerotic plaques, and that the presence of fibrin can promote their growth, being involved in the progression of atherosclerosis [17].

It is unclear whether DM2 is a modulator of fibrin clot phenotype which is potent enough to alter the fibrin variables modified already by a number of prothrombotic mechanisms that operate in advanced CAD. It has been demonstrated that acute hyperglycemia observed in up to 50% of acute MI patients could significantly reduce the efficiency of fibrinolysis but had no effect on clot permeability [9]. In advanced atherosclerosis, the effect of DM2 on fibrin clot properties appeared to be weaker and overruled by the impact of other factors, including hyperhomocysteinemia and elevated C-reactive protein [18]. Despite the fact that more tightly packed and less porous fibrin structure has been observed more often in CAD patients who experienced stent thrombosis in the past, the effect of DM2 on clot properties in this population was negligible [19]. On the other hand, treatment with insulin or biguanide has been shown to make fibrin more permeable [20, 21]. Similarly, statin treatment can improve fibrin clot characteristics in subjects with increased cardiovascular risk [9, 22].

The aim of this study was to evaluate the fibrin clot permeability and susceptibility to lysis in CAD patients with concomitant DM2 and determine factors that may account for alterations in fibrin clot properties in such high-risk population.

Methods

In this case–control study, we recruited 67 consecutive white patients (44 males and 23 females) with CAD (angiographically documented ≥70% stenosis in at least one epicardial coronary artery) and documented DM2, scheduled for elective coronary artery bypass grafting surgery (CABG). Diabetes was defined as a history of diabetes regardless of disease duration, need for hypoglycemic agents, or fasting plasma glucose ≥126 mg/dL (7 mmol/L) on two separate occasions. Exclusion criteria were: cancer, acute illness, atrial fibrillation, liver injury, acute coronary syndrome within the previous 6 weeks. Medications were administered in unchanged doses for at least 2 weeks before surgery. A control group comprised 65 non-diabetic CAD patients (49 males and 16 females), scheduled for CABG at the same time and matched for age, gender, and smoking habits. All patients signed an informed consent. The study was approved by the Ethics Committee of the Jagiellonian University.

All subjects calculated an individual body mass index (BMI) using the standard formula: body mass in kilograms divided by the square of height in meters.

Blood samples were drawn from an antecubital vein with a minimal stasis prior to surgery. Lipid profile and glucose was determined by routine laboratory methods. Fibrinogen was determined using the von Clauss method. High-sensitivity C-reactive protein (CRP) was measured by nephelometry (Dade Behring). Commercially available immunoenzymatic assays were used to determine fibrinolytic proteins, including plasma plasminogen activator inhibitor-1 antigen (PAI-1; American Diagnostica, Stamford, CT, USA), tPA (Diagnostica Stago, Asnieres, France), thrombin activatable fibrinolysis inhibitor antigen (TAFI; Chromogenix, Lexington, Massachusetts, United States), von Willebrand factor (vWF; Diagnostica Stago, Asnieres, France), and also platelet activation markers, soluble CD40 ligand (sCD40L; R&D Systems, Indianapolis, IN, USA), and P-selectin (R&D Systems). All the intra-assay and inter-assay coefficients of variation for the ELISA measurements were below 7%.

Fibrin clot permeability, expressed as a permeation coefficient ($K_p$), which indicates the pore size, was determined as described [22]. Clot lysis time was determined using a turbidity assay with slight modifications [22]. Briefly, citrated plasma was diluted with the Tris buffer, containing 20 mmol/L CaCl$_2$, 1 U/mL human thrombin (Sigma) and 1 μg/mL recombinant tPA (Boehringer Ingelheim, Ingelheim, Germany). The time required for a 50% decrease in clot turbidity ($t_{50\%}$) was determined [22]. All measurements were performed by technicians blinded to the sample status. The coefficients of intra- and inter-assay variations were 5–6%.

Statistical analysis

The study was powered to have a 80% chance of detecting a 5% difference in plasma clot permeability and lysis time using a $p$ value of 0.05. In order to demonstrate such a difference or greater, 52 patients were required in each group. For a $p$ value of 0.01, 77 patients per group were required.

Continuous variables are expressed as mean ± SD or median (interquartile range) and categorical variables as
number (percentage). Continuous variables were checked for normal distribution with Shapiro–Wilk test and compared by Student’s t test or the Mann–Whitney U test as appropriate. The Pearson or Spearman rank correlation coefficients were calculated to test the association between two variables with a normal or non-normal distribution, respectively. The influence of different therapy of diabetes on fibrin clot properties was checked with Kruskal–Wallis ANOVA with multiple comparisons test. All clinical and laboratory variables that showed the association with \( K_s \) or \( t_{50\%} \) in univariate model (\( p < 0.2 \)) and did not show substantial correlations (\( r > 0.5 \)) with another independent variable were then included in the multiple linear regression analysis to determine predictors of \( K_s \) and \( t_{50\%} \) in the study population. A \( p \) value < 0.05 was considered statistically significant.

## Results

As shown in Table 1, diabetic and non-diabetic groups were similar in terms of demographic variables and cardiovascular risk factors except BMI, which was 9 % higher in the former group (\( p < 0.001 \)). A larger proportion of diabetic patients received angiotensin converting enzyme inhibitors (ACEI; \( p = 0.001 \)). Twenty-six patients in the diabetic group received insulin alone, 27 were on oral agents, while 7 patients were only on the diet. As expected, diabetic patients had higher fasting glucose (+24.3 %, \( p < 0.001 \)) and fibrinogen levels (+9.0 %, \( p = 0.037 \)). Elevated PAI-1 (+58.7, \( p < 0.001 \)), tPA (+24.0 %, \( p < 0.001 \)) antigens, but not TAFI, were observed in the diabetic group. Interestingly, P-selectin was increased (+12.2 %, \( p < 0.001 \)) in the diabetic group. vWF and CD40L were similar in both groups (Table 2).

| Table 2 Laboratory investigations |
|----------------------------------|
|                              | Diabetic subjects | Control subjects | \( p \) value |
| Glucose (mmol/l)               | 6.8 (5.6–8.0)     | 5.3 (4.8–5.6)    | <0.001       |
| Total cholesterol (mmol/l)     | 4.91 (4.18–5.39)  | 4.53 (3.89–5.41) | 0.40         |
| Triglycerides (mmol/l)         | 1.55 (1.21–1.96)  | 1.48 (1.10–1.79) | 0.25         |
| HDL cholesterol (mmol/l)       | 1.24 (1.09–1.48)  | 1.31 (1.12–1.52) | 0.29         |
| LDL cholesterol (mmol/l)       | 2.89 (2.42–3.64)  | 2.75 (2.32–3.57) | 0.33         |
| Platelets (\( \times 10^9/\text{mm}^3 \)) | 213 (177–248)     | 219 (179–253)    | 0.69         |
| Creatinine (\( \text{mmol/L} \)) | 77 (43–172)      | 84 (43–154)      | 0.42         |
| CRP (mg/l)                     | 2.60 (1.65–4.41)  | 2.34 (1.64–4.33) | 0.28         |
| Fibrinogen (g/l)               | 4.43 (3.45–4.96)  | 3.87 (3.18–4.82) | 0.037        |
| PAI-1 (ng/ml)                  | 65.4 (47.9–78.0)  | 27.0 (21.4–35.0) | <0.001       |
| TAFI (%)                       | 103 (93–117)      | 106 (99–113)     | 0.76         |
| tPA (ng/ml)                    | 10.4 (9.0–11.1)   | 7.9 (6.5–9.9)    | <0.001       |
| vWF (IU/ml)                    | 108 (100–129)     | 108.0 (100–119)  | 0.31         |
| sCD40L (ng/ml)                 | 1.04 ± 0.24       | 0.97 ± 0.27      | 0.10         |
| P-selectin (ng/ml)             | 199.4 ± 34.3      | 175.1 ± 39.8     | <0.001       |
| \( K_s \) (\( 10^{-3}\text{cm}^2/\text{s} \)) | 7.70 ± 1.34      | 8.20 ± 0.92      | 0.02         |
| \( t_{50\%} \) (min)          | 9.42 ± 1.47       | 8.94 ± 1.23      | 0.04         |

Data are shown as X ± SD or median (IQR)

\( HDL \) high-density lipoprotein, \( LDL \) low-density lipoprotein, \( CRP \) C-reactive protein, \( PAI-1 \) plasminogen activator inhibitor-1, \( TAFI \) thrombin activatable fibrinolysis inhibitor, \( tPA \) tissue plasminogen activator, vWF von Willebrand factor, sCD40L soluble CD40 ligand, \( K_s \) permeation coefficient, \( t_{50\%} \) clot lysis time

As expected, diabetic patients had higher fasting glucose (+24.3 %, \( p < 0.001 \)) and fibrinogen levels (+9.0 %, \( p = 0.037 \)). Elevated PAI-1 (+58.7, \( p < 0.001 \)), tPA (+24.0 %, \( p < 0.001 \)) antigens, but not TAFI, were observed in the diabetic group. Interestingly, P-selectin was increased (+12.2 %, \( p < 0.001 \)) in the diabetic group. vWF and CD40L were similar in both groups (Table 2).

CAD patients with DM2 had different fibrin clot parameters compared with the non-diabetic controls. \( K_s \) was 6.1 % lower in the diabetic group (\( p = 0.02 \)) while \( t_{50\%} \) was 5.1 % longer in patients with DM2 (\( p = 0.04 \)). There were no significant differences in \( t_{50\%} \) between patients receiving various hypoglycemic therapy (\( p = 0.10 \) (Fig. 1)). However, patients treated with oral hypoglycemic drugs had 16.9 % lower \( K_s \) than those treated with diet only (\( p < 0.02 \)) and subjects receiving insulin had 14.6 % lower \( K_s \) than those on dietary treatment only (\( p < 0.09 \) (Fig. 1)).

In diabetic group the inverse associations between \( K_s \) and TAFI \( (r = -0.36, \ p = 0.003) \), PAI-1 \( (r = -0.38, \ p = 0.001) \) and TAFI \( (r = -0.38, \ p = 0.001) \).
p = 0.001), tPA (r = −0.27, p = 0.03) were observed (Table 2). There were also negative correlations between Ks and P-selectin (r = −0.40, p = 0.001; Fig. 3) and vWF (r = −0.47, p < 0.001; Fig. 2). Moreover, sCD40L and Ks (r = −0.24, p = 0.06) tended to show inverse correlation in the diabetic group. Similar correlations were not seen in the non-diabetic CAD patients (data not shown).

In patients with DM2 but not in the non-diabetic group, there was a positive correlation between t50% and CRP (r = 0.31, p = 0.01). The positive associations t50% with TAFI (r = 0.53, p < 0.001) and tPA (r = 0.37, p = 0.002) were demonstrated. In addition, PAI-1 had also positive associations with Ks in diabetic (r = 0.57, p < 0.001) and non-diabetic patients (r = 0.62, p < 0.001). In the both groups, fibrinogen, P-selectin, vWF were positively correlated with t50% (diabetic group (Fig. 3): r = 0.41, p < 0.001; r = 0.51, p < 0.001; r = 0.71, p < 0.001, respectively; non-diabetic group: r = 0.52, p < 0.001; r = 0.36, p = 0.003; r = 0.49, p < 0.001, respectively). Only in the control group, sCD40L was correlated with t50% (r = 0.26, p = 0.037).

A multiple linear regression analysis was performed to determine the independent effect of laboratory and clinical variables on Ks and t50%. Before the inclusion to the multiple model, significant correlations between independent variables have been found. Ks was strongly correlated with t50% (r = −0.67; p < 0.001), vWF (r = −0.43; p < 0.001), PAI-1 (r = −0.37; p < 0.001), and P-selectin (r = −0.29; p = 0.001). t50% was significantly correlated with vWF (r = 0.64; p < 0.001), PAI-1 (r = 0.49; p < 0.001), P-selectin (r = 0.46; p < 0.001), fibrinogen (r = 0.46; p < 0.001), TAFI (r = 0.39; p < 0.001), and CRP before CABG (r = 0.30; p < 0.001). P-selectin was correlated with PAI-1 (r = 0.47; p < 0.001), and fibrinogen (r = 0.29; p = 0.001) whereas PAI-1 with t-PA (r = 0.38; p < 0.001), and vWF (r = 0.44; p < 0.001). Fibrinogen was correlated with CRP (r = 0.53; p < 0.001), platelet count (r = 0.37; p < 0.001), and vWF (r = 0.30; p < 0.001). Finally, the multivariate model for the whole study population showed that vWF, PAI-1, fibrinogen and diabetes mellitus were the independent predictors of t50% (R² = 0.58, p < 0.001; Table 3) whereas vWF was the only independent predictor of Ks (R² = 0.22, p < 0.001; Table 3).

**Discussion**

The present study shows that DM2 is associated with decreased clot permeability and susceptibility to lysis in patients with severe CAD. A strong modulatory effect of DM2 on plasma fibrin clot phenotype has been observed in the presence of several factors leading also to the formation of more dense and less lysable clots such as smoking, hypertension and elevated CRP levels [10].
Dunn et al. [8] have reported that the fibrin clots formed from fibrinogen obtained from patients with DM2 had denser, less porous structure than controls. That was related to glycemic control but they had excluded CAD patients. The lack of associations between both fibrin variables and glycemia indicates that other factors may account for alterations in fibrin clot phenotype in CAD patients.

Platelet activation is a well known modifier of fibrin clot properties. It has been shown that altered clot properties can be caused by a number of platelet-derived proteins mainly released at the sites of platelet aggregation [23]. Polyphosphates secreted from dense granules can alter the formation of fiber aggregates [24]. In the presence of activated platelets, a fibrin clot may have a different architecture with local increase in fiber density [25]. Moreover, it has been demonstrated that the use of anti-platelet agents in patients with DM2 can overcome to some extent the potential effects of poor glycemic control on platelet reactivity [26]. Our study shows that P-selectin, which is expressed in alpha-granules of activated platelets, was increased in patients with DM2 and CAD compared with non-diabetic subjects. Another platelet marker, sCD40L, which did not differentiate diabetic and non-

| Dependent variable | Independent variable | Contribution of variance, % | p      | β     |
|-------------------|----------------------|-----------------------------|--------|-------|
| Ks                | vWF                  | 10.5                        | <0.0001 | -0.36 |
|                   | Diabetes mellitus    | 2.1                         | 0.07   | -0.15 |
|                   | TAFI                 | 1.2                         | 0.10   | -0.13 |
|                   | ACEI                 | 0.04                        | 0.85   | -0.02 |
|                   | CRP                  | 0.01                        | 0.95   | -0.01 |
| t50%              | vWF                  | 16.4                        | <0.0001 | 0.43  |
|                   | PAI-1                | 16.3                        | <0.0001 | 0.45  |
|                   | Fibrinogen           | 5.5                         | 0.0004 | 0.23  |
|                   | Diabetes mellitus    | 9.1                         | 0.002  | -0.30 |
|                   | ACEI                 | 0.36                        | 0.33   | 0.06  |

Abbreviations: see Tables 1 and 2

Fig. 2 Correlation between permeation coefficient (Ks) and von Willebrand factor (vWF) and P-selectin in diabetic patients

Fig. 3 Correlation between clot lysis time (t50%) and von Willebrand factor (vWF) and P-selectin in diabetic patients
diabetic CAD patients, showed weaker or no associations with fibrin parameters in the current study. This provides evidence for a role of platelet activation in altering the fibrin clot structure in diabetic CAD patients.

An original finding is a strong association between vWF and clot properties, both permeability and lysis, observed in advanced CAD. Interestingly, in this patient group vWF was a predictor of $K_s$, indicating novel associations linking endothelial dysfunction with fibrin clot properties measured ex vivo. Endothelial dysfunction implies an alteration in endothelial integrity and, as such, may be assessed by flow-mediated dilatation or by changes in circulating markers, such as plasma vWF [27]. It remains to be established whether vWF per se might actively alter plasma fibrin network properties.

TAFI combines fibrinolysis with coagulation cascade [28]. There have been previous studies showing increased [29–31] or decreased TAFI levels [32, 33] in CAD patients. There have been, however, few reports evaluating the effect of TAFI on clot lysis time in diabetic subjects that demonstrated no effect [34] or hypofibrinolysis [35]. In the present study, despite similar TAFI levels in both groups, we found associations between permeability, lysis time and TAFI only in the diabetic CAD group. The impact of TAFI on plasma fibrin clot phenotype in DM2 merits further investigation.

Given the fact that in both groups, a significant percentage of CAD patients was taking statins, which have been reported to increase the clot permeability and lysis time [9, 22], it might be concluded that both drugs, though they can improve clot phenotype, were not able to abolish a complex effect of DM2 on fibrin variables [9, 11, 13]. Of note, there were differences in clot permeability associated with the mode of treatment of DM2. Taking into account the previous findings [20, 21], this probably resulted from disease severity and a specific effect of insulin or oral antidiabetic agents.

In the present study, PAI-1, fibrinogen and DM2 have been found to be the independent predictors of $t_{50\%}$, and vWF both $t_{50\%}$ and $K_s$. PAI-1 is protein mostly released from the endothelium and from blood platelets. It is responsible for impaired fibrin clot degradation in platelet-rich plasma. It appears that coexistence of atherosclerosis and DM2 might markedly enhance influence of the endothelial cell and the platelet activation on $t_{50\%}$. This surprising finding deserves further investigation.

Several limitations of our study warrant consideration. First, the size of this study is limited. Nevertheless, diabetic patients were matched with the non-diabetic group for most parameters. Second, glycated hemoglobin HbA1c was not determined. Third, imaging analysis using scanning electron microscopy was not performed. Nevertheless, sample preparation including dehydration hampers the extrapolation of microscopic findings to the in vivo conditions.

In conclusion, our observations indicate that the DM2 is potent enough to unfavorably affect the plasma fibrin clot characteristics despite the altered clot phenotype as typically observed in advanced CAD. In this clinical study platelet and endothelial markers appear to contribute to fibrin clot properties in CAD concomitant with DM2. Further studies are needed to determine the mechanism of the altered fibrin clot structure formation in patients with DM2 and advanced CAD.

Acknowledgments The project was supported by a grant of Jagiellonian University Medical College No. K/ZDS/002936 (to A.U.).

Conflict of interest The authors state that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Laakso M (2001) Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 249:225–235
2. Mohan V, Venkatraman JV, Pradeepa R (2010) Epidemiology of cardiovascular disease in type 2 diabetes: the Indian scenario. J Diabetes Sci Technol 4:158–170
3. Kannel W, McGee D (2002) Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035–2038
4. Polakowska M, Piotrowski W (2011) Incidence of diabetes in the Polish population: results of the Multicenter Polish Population Health Status Study—WOBASZ. Pol Arch Med Wewn 121:156–163
5. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), Eur Heart J 28:88–136
6. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT (2000) Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102:2180–2184
7. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A et al (2006) Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 26:2567–2573
8. Dunn EJ, Ariëns RA, Grant PJ (2005) The influence of type 2 diabetes on fibrin structure and function. Diabetologia 48:1198–1206
9. Undas A (2011) Acquired dysfibrinogenemia in atherosclerotic vascular disease. Pol Arch Med Wewn 121:110–119
10. Undas A, Ariëns RA (2011) Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 31:e88–e99
11. Dunn EJ, Philippou H, Ariëns RA, Grant PJ (2006) Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49:1071–1080
12. Zabczyk M, Butenas S, Palka I, Nessler J, Undas A (2010) Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy. Pol Arch Med Wewn 120:334–340
13. Pieters M, Covic N, du Looits T, van der Westhuizen FH, van Zyl DG, Rheeder P et al (2006) The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects. Thromb Haemost 96:623–629
14. De Luca G, Verdoia M, Cassetti E, Schaffer A, Cavallino C, Bolzani V, Marino P; Novara Atherosclerosis Study Group (NAS) (2011) High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. J Thromb Thrombolysis 31:458–463
15. D’Ascenzo F, Bollati M, Clementi F, Castagno D, Lagersqvist B, de la Torre Hernandez JM, et al (2012) Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol 2012 Feb 21. [Epub ahead of print]
16. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G (1984) Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311:501–505
17. Bini A, Fenoglio J, Mesa-Tejada E, Kudryk B, Kaplan K (1989) Identification and distribution of fibrinogen, fibrin, and fibrin(o-gen) degradation products in atherosclerosis. Atherosclerosis 9:1038–1045
18. Undas A, Brozek J, Jankowski M, Siodak Z, Szczeklik A, Jakubowski H (2006) Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subject. Arterioscler Thromb Vasc Biol 26:1397–1404
19. Undas A, Zalewski J, Krocini M, Siodak Z, Sadowski M, Pre- gowski J, Dudek D, Janion M, Witkowski A, Zmudka K (2010) Altered plasma fibrin clot properties are associated with in-stent thrombosis. Arterioscler Thromb Vasc Biol 30:276–282
20. Jornske Hogan LO, Wallen NH, Yngen M, Blomback M (2003) Increased plasma fibrin gel porosity in patients with type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 1:1195–1201
21. Standeven KF, Ariëns RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ (2002) The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 51:189–197
22. Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A (2006) Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 4:1029–1036
23. Wiesel J (2007) Structure of fibrin: impact on clot stability. J Thromb Haemost 5:116–124
24. Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariëns RA (2010) Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 115:3980–3988
25. Collet JP, Montalescot G, Lesty C, Weisel JW (2002) A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet rich clots. Circ Res 90:428–434
26. Mangiacapra F, Peace AJ, Wijns W, Barbato E (2011) Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopi-dogrel. J Thromb Thrombolysis 32:54–58
27. Bajzar L, Morser J, Nesheim ME (1996) TAFI, or plasma pro- carboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J Biol Chem 271:16603–16608
28. Boffa MB, Koschinsky ML (2007) Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 40:431–442
29. Schroeder V, Wilmer M, Buehler B, Kohler HP (2006) TAFI activity in coronary artery disease: a contribution to the current discussion on TAFI assays. Thromb Haemost 96:236–237
30. Zorio E, Castello R, Falco C, Espina F, Osa A, Almenar L, Aznar J, Estelles A (2003) Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 122:958–965
31. Melzler ME, Doggen CJ, de Groot PG, Meijers JC, Rosendaal FR, Lismann T (2009) Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica 94:811–818
32. Santamaria A, Borrell M, Oliver A, Ortin R, Forner R, Coll I, Mateo J, Souto JC, Fontcuberta J (2004) Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population. Am J Hematol 76:348–352
33. Antovic JP, Yngen M, Ostenson CG, Antovic A, Wallen HN, Jornske G, Blomback M (2003) Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications. Blood Coagul Fibrinolysis 14:551–556
34. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y (2002) Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 87:605–660